Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Non-Current Deferred Tax Liability for 10 consecutive years, with $30.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability changed 0.19% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $30.0 million (changed 0.19% YoY), while the FY2025 annual figure was $30.0 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability steadied at $30.0 million in Q1 2026 per RARE's latest filing, from $30.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $33.3 million in Q1 2022 and bottomed at $30.0 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $31.0 million across 5 years, with a median of $30.1 million in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability changed 0.0% — and 2023, when it dropped 5.08%.
• Ultragenyx Pharmaceutical's Non-Current Deferred Tax Liability stood at $31.7 million in 2022, then decreased by 5.08% to $30.1 million in 2023, then retreated by 0.19% to $30.0 million in 2024, then changed by 0.0% to $30.0 million in 2025, then changed by 0.0% to $30.0 million in 2026.
• Business Quant data shows RARE's Non-Current Deferred Tax Liability at $30.0 million in Q1 2026, $30.0 million in Q4 2025, and $30.1 million in Q3 2025.